Last reviewed · How we verify
Vicagrel
Vicagrel is a Small molecule drug developed by Jiangsu vcare pharmaceutical technology co., LTD. It is currently in Phase 3 development.
Vicagrel is a small molecule that has been studied in clinical trials for conditions such as Acute Coronary Syndrome, Coronary Artery Disease, and Percutaneous Coronary Intervention. It has been investigated in various doses, including 5mg and 6mg, as part of clinical trials to evaluate its pharmacokinetics and pharmacodynamics.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Vicagrel |
|---|---|
| Sponsor | Jiangsu vcare pharmaceutical technology co., LTD |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic/Pharmacodynamic Study of Vicagrel Capsules and Clopidogrel Tablets in Healthy CYP2C19 Normal Metabolizers (PHASE1)
- Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) (PHASE3)
- PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers (PHASE1)
- Assessment of the Effect of Omeprazole on Vicagrel in Healthy Subjects (PHASE1)
- A Clinical Trial to Evaluate the Effect of Food on PK and PD of Vicagrel Capsules in Healthy Adult Subjects (PHASE1)
- The Mass Balance and Biotransformation of [14C] Vicagrel in Healthy Man (PHASE1)
- The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel (PHASE2)
- Pharmacokinetics and Pharmacodynamics of Vicagrel in Healthy Adult Subjects of Different CYP2C19 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vicagrel CI brief — competitive landscape report
- Vicagrel updates RSS · CI watch RSS
- Jiangsu vcare pharmaceutical technology co., LTD portfolio CI
Frequently asked questions about Vicagrel
What is Vicagrel?
Who makes Vicagrel?
What development phase is Vicagrel in?
Related
- Manufacturer: Jiangsu vcare pharmaceutical technology co., LTD — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing